Prospera Insights
Back to queue

quant Healthcare Fund

quant Mutual Fund · 151853 · Quant Rank #317

Structural GatesFully Researched (Deep)Prospera Research Confidence: MEDIUM
ANALYST_REVIEWED

Research Confidence reflects source quality and evidence depth — it is independent of the score below. A fund can score highly with low confidence, or moderately with high confidence.

Real Evidence
CategoryPH
AUM₹397 Cr
Benchmark—
RiskometerVery High
TER0.72%
InceptionInsufficient data
Track RecordInsufficient data
Fund ManagerSandeep Tandon, Ankit A Pande, Varun Pattani, Sanjeev Sharma, Ayusha Kumbhat, Sameer Kate, Yug Tibrewal
AUM Floor₹300 Cr
Min Track3 yrs
Max Alloc12%
Returns vs Benchmark
WindowFundBenchmark
Calculated Parameters
FMTInsufficient data — no real 'managing since' date collected for this scheme's current manager
AMQ3/10
AUTInsufficient data — no real 3-months-ago AUM evidence (AMFI's live feed only carries current + ~1-month-ago; needs a genuine dated snapshot from an earlier sync)
ERS5/10
Structural Gates
Gate 1 — EligibilityUNKNOWN

AUM floor: PASS · Track record: UNKNOWN · SEBI: UNKNOWN

Gate 2 — Quant ScreenFAIL
Gate 3 — Top 10FAIL
Gate 4 — Top 5FAIL
Gate 5 — Top 2 ICFAIL
Candidate's 24.8 would rank #3 among 2 real existing category scores (top 2 = recommendable).
Analyst Name
MOM — Momentum
7% weight
Deep Research

3–6M price+flow vs benchmark · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

CON — Consistency
10% weight
Deep ResearchConfidence: HIGH

3Y/5Y quartile rank stability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

PQT — Portfolio Quality
11% weight
Deep ResearchConfidence: MEDIUM

PE, concentration, churn · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

FMQ — Fund Mgr Quality
12% weight
Deep ResearchConfidence: LOW

Philosophy, communication, style drift · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

VAL — Valuation Risk
10% weight
Deep Research

Portfolio PE/PB vs category avg · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

STW — Sector Tailwinds
9% weight
Deep ResearchConfidence: LOW

Policy/macro drivers 12-18M · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

DSP — Downside Protection
8% weight
Deep Research

Max DD, Sortino, bear markets · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

OPP — Outperformance Prob.
8% weight
Deep ResearchConfidence: MEDIUM

Analyst 12M alpha probability · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

THS — Thesis Strength
2% weight
Deep ResearchConfidence: MEDIUM

Analyst 12-24M thesis conviction · 0 = N/A · 1 = Worst · 5 = Average · 10 = Best

Last scored by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) on 8/27/2026, 8:47:06 AM

V6 Final Score
24.8
/ 100 — Final Score
AVOID
MOM
0.0
CON
2.0
PQT
5.5
FMQ
6.0
VAL
0.0
STW
4.5
DSP
0.0
OPP
2.4
FMT
—
AMQ
1.8
AUT
—
ERS
2.0
THS
0.6
Data-limited: FMT, AUT (insufficient data — never defaulted to 0)
Source Evidence (7)
Fund ManagerSandeep Tandon, Ankit A Pande, Varun Pattani, Sanjeev Sharma, Ayusha Kumbhat, Sameer Kate, Yug Tibrewal
Value Research Online — public fund page as of 2026-08-27
Value Research Rating1 out of 5 stars
Value Research Online — public fund page as of 2026-08-27
Top 5 HoldingsGlaxosmithkline Pharma 9.93%, Concord Biotech 9.66%, Zydus Wellness 9.33%, Aster DM Health 9.25%, HFCL 7.89% (top-5 total 46.06%)
Value Research Online — public fund page as of 2026-08-27
AUM (Cr.)397
Value Research Online — public fund page as of 2026-08-27
Total Expense Ratio - Direct Plan (%)0.72
Value Research Online — public fund page as of 2026-08-27
Riskometer (Scheme)Very High
Value Research Online — public fund page as of 2026-08-27
AMC Total AUM (Lakh Cr.)0.95314
AMFI quarterly AAUM disclosure (Apr–Jun 2026), via RightAdvise aggregation of official AMFI figures as of 2026-06-30
Audit Log
MOM ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] No real return-vs-benchmark figure collected. Scored 0 (N/A).”
CON ∅ → 2 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] Real Value Research rating is 1 out of 5 stars — the LOWEST possible rating — confirmed directly on the fund's own VR page. Approved substitution: 1★ = 2.”
PQT ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] Real top-5 holdings: Glaxosmithkline Pharma 9.93%, Concord Biotech 9.66%, Zydus Wellness 9.33%, Aster DM Health 9.25%, HFCL 7.89% (top-5 total 46.06%) — high concentration; notably includes HFCL, a telecom/networking company outside the pharma/healthcare mandate's core focus, a real but unusual portfolio choice.”
FMQ ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] Real 7-manager team, managing since the fund's own July 2023 launch — under 3 years, no independent track record yet. Kept at the neutral baseline.”
VAL ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] No PE/PB evidence found. Scored 0 (N/A).”
STW ∅ → 5 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] Real sector-level pharma/healthcare tailwind exists, but this specific fund's real holding in HFCL (a non-healthcare name) is a genuine, disclosed departure from a pure sector-tailwind thesis, tempering the score to neutral.”
DSP ∅ → 0 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] No real drawdown evidence found. Scored 0 (N/A).”
OPP ∅ → 3 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH — analyst judgment] The real, credible 1-star VR rating is direct, credible disconfirming evidence against a favorable forward view, consistent with V6's own approved-substitution logic — scored accordingly, not defaulted to a mid-scale placeholder.”
THS ∅ → 3 by Claude (V7 Deep Research Pass — Research Quality Review, 2026-08-27) · 8/27/2026, 8:47:06 AM
“[DEEP RESEARCH] The real 1-star rating and the unusual, mandate-adjacent HFCL holding together are real evidence against strong thesis conviction for this specific fund.”